DSP-2230

DSP-2230
Clinical data
Routes of; administration	By mouth
Identifiers
	IUPAC name (2S)-2-[[[3-cyclobutyl-5-(3,4,5-trifluorophenoxy)-3H-imidazo[4,5-b]pyridin-2-yl]methyl]amino]propanamide;
CAS Number	1233231-30-5 ;
UNII	LSY2D22FBK;
ChEMBL	ChEMBL3545012;
Chemical and physical data
Formula	C20H20F3N5O2
Molar mass	419.408 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES FC1=CC(OC2=CC=C(N=C3CN([C@@H](C(N([H])[H])=O)C)[H])C(N3C4CCC4)=N2)=CC(F)=C1F;
	InChI InChI=1S/C20H20F3N5O2/c1-10(19(24)29)25-9-16-26-15-5-6-17(27-20(15)28(16)11-3-2-4-11)30-12-7-13(21)18(23)14(22)8-12/h5-8,10-11,25H,2-4,9H2,1H3,(H2,24,29)/t10-/m1/s1; Key:HHXCJIMPEJSJTG-SNVBAGLBSA-N;

DSP-2230 is a selective small-molecule Na_v1.7 and Na_v1.8 voltage-gated sodium channel blocker which is under development by Dainippon Sumitomo Pharma for the treatment of neuropathic pain.^[1]^[2] As of June 2014, it is in phase I/phase II clinical trials.^[1]^[2]

References

^ ^a ^b Martz L (2014). "Nav-i-gating antibodies for pain". Science-Business EXchange. 7 (23): 662. doi:10.1038/scibx.2014.662. ISSN 1945-3477.
^ ^a ^b Bagal SK, Chapman ML, Marron BE, Prime R, Storer RI, Swain NA (August 2014). "Recent progress in sodium channel modulators for pain". Bioorganic & Medicinal Chemistry Letters. 24 (16): 3690–9. doi:10.1016/j.bmcl.2014.06.038. PMID 25060923.